EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients.
Recent Searches
Yukie Yoshii
EY Entrepreneurial Winning Women™ Asia-Pacific Class of 2026
Founder, President and CEO, LinqMed Inc., Japan
Yukie Yoshii is the founder, president and CEO of LinqMed Inc., a Japanese healthcare solutions provider established in 2022. LinqMed develops innovative “visible” cancer therapeutics based on the radioisotope Copper-64. LinqMed’s lead program, ⁶⁴Cu-ATSM for malignant brain tumors, is currently in Phase III clinical trial, while a separate program for pancreatic cancer is in Phase I evaluation.
At LinqMed, Yukie advances theranostic solutions that unite diagnosis and therapy, enabling patients to be imaged with Positron Emission Tomography (PET) and treated using the same Copper-64-based agent. Under her leadership, LinqMed has built GMP (Good Manufacturing Practice) capabilities and established global collaborations to accelerate clinical translation. Guided by the vision “Link for Life,” Yukie is dedicated to connecting frontier science with practical medicine to improve patient outcomes.
She earned her bachelor’s degree and PhD in Science from the University of Tsukuba. She began her academic career at the University of Fukui and spent over a decade at Japan’s National Institutes for Quantum Science and Technology, where she led research in radiotherapeutics for oncology.
Over the next three to five years, she aims to execute a hybrid growth strategy focused on expanding the company’s pipeline, platform, and CMO businesses, targeting significant revenue growth and leadership in image-guided radiotherapy.
Yukie has received numerous accolades, including the Grand Prize at the JHVS 2024 Venture Awards and the Excellence Award for Women Entrepreneurs at the DBJ New Business Plan Competition for Women in 2022.
Our vision, ‘Link for Life,’ is to connect frontier science with real-world medicine to advance innovative, ‘visible’ radiopharmaceutical cancer therapies. We founded LinqMed to serve patients, families and clinicians. Success in this cutting-edge field demands collaboration across disciplines; we convene and connect people to transform breakthrough research into trusted care.